908 Devices Inc. develops purpose-built handheld chemical analysis devices for point-of-need use in health, safety and defense technology applications. Its news centers on Mass Spec and FTIR product activity, installed-device growth, recurring revenue, and applications such as narcotics identification, toxic exposure screening and security-threat analysis.
Company updates also cover acquisitions and portfolio expansion, including the completed purchase of NIRLAB AG and its AI-powered, cloud-connected near-infrared spectroscopy platform for narcotics screening. Other recurring items include quarterly financial results, revenue outlooks, executive and strategy appointments, funded partnership revenue, and investor conference participation.
908 Devices (Nasdaq: MASS), a leading developer of handheld and desktop devices for chemical and biochemical analysis, announced its participation in two upcoming investor conferences. The company will host a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas, on May 29 at 8:00 a.m. CT. Additionally, 908 Devices will present at the William Blair 44th Annual Growth Stock Conference in Chicago, Illinois, on June 4 at 10:40 a.m. CT. Live and archived webcasts of these events will be available on their website.
908 Devices Inc. (Nasdaq: MASS) reported 5% revenue growth in Q1 2024 compared to Q1 2023, reaching $10 million. Handheld revenue increased by 20%, while desktop revenue decreased by 18%. Recurring revenue was $4.5 million, with 45% of total revenue being recurring. The company acquired RedWave Technology, published its inaugural ESG report, and ended the quarter with $134.2 million in cash and no debt. Gross profit was $5.0 million, net loss was $10.9 million, and EPS was $0.33. Operating expenses were $17.7 million. The company expects 2024 revenue to be $63.0-65.0 million, a 25-29% increase over 2023.
908 Devices Inc. (Nasdaq: MASS) has acquired RedWave Technology, enhancing its forensic product offerings through the addition of optical spectroscopy technology. This move expands 908 Devices' handheld and desktop mass spec devices for chemical and biochemical analysis. The acquisition enables the company to offer a wider range of analytical devices for forensic workflows, including rapid chemical identification of bulk materials using FTIR spectroscopy. RedWave's innovative products are expected to boost 908 Devices' revenue and strategic objectives, with a purchase consideration of $53.5 million, including cash and common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.